Vitalis Therapeutics Inc. — IND 168,442 for VitaFlow (VTX-401): what an IND actually is, what was filed, the thirty-day rule, the clinical hold authority, the 99 submissions made to it since, and how it differs from the NDA it exists to make possible.
1. What an IND Actually Is
Federal law prohibits shipping an unapproved drug across state lines. That prohibition would make clinical research impossible, so the regulations provide an exemption.
The distinction sounds pedantic and it is not. It explains three things that otherwise look strange:
• Why there is no approval. Nobody grants an IND. It takes effect by operation of the regulation.
• Why silence means proceed. If the agency does not act within thirty days, the exemption applies.
• Why the burden sits with the sponsor throughout. The sponsor is operating under an exemption it claimed. It is not executing a permission somebody checked.
| Number | IND 168,442 |
| Submitted | 2024-09-06 |
| Effective | 2024-10-06 — thirty days later, automatically |
| Authorized at | Gate 2, 2024-09-30 — a submission gate releasing no tranche |
| Status at 15 Oct 2026 | Open and active at the status date |
| Clinical holds | 0 |
2. What Was Filed
| Component | What it is | Note |
|---|---|---|
| Form FDA 1571 | The cover application | Names the sponsor, the drug, the phase, and every party to whom obligations have been transferred (see CRO Oversight). |
| Introductory statement and general investigational plan | What the drug is and where the program is going | Broad. Nobody is held to a Year 4 plan written in Year 1. |
| Investigator's Brochure | The safety and pharmacology reference for investigators | Becomes the yardstick for 'unexpected' in expedited safety reporting. |
| Protocol(s) | The study or studies to be conducted under this submission | Phase 1 only at the original IND. Later phases arrive as protocol amendments. |
| Chemistry, manufacturing and control | Enough to establish the material is safe to dose | Far less than an NDA requires — the question is safety of the clinical supply, not commercial process validation. |
| Pharmacology and toxicology | The nonclinical package supporting human exposure | The GLP studies. This is what the Pre-IND meeting was about. |
| Previous human experience | Any prior exposure, anywhere | Empty for a new molecular entity, and that emptiness is the point. |
That makes it load-bearing in a way its format does not suggest. As the Safety Reporting Plan sets out, an event not listed in the current IB, or listed at lower severity than observed, is unexpected — and unexpected plus serious plus causally suspected starts a fifteen-day clock. Updating the IB changes the program's reporting obligations.
Note how little CMC an IND requires compared with an NDA. The question at IND is whether the clinical supply is safe to dose, not whether a commercial process is validated. The CMC Readiness Assessment describes the gap that has to be closed between the two — and closing it took most of the program.
The last row is worth pausing on. “Previous human experience” is empty, and that emptiness is the entire justification for the nonclinical package. Everything known about how this molecule behaves in a living system comes from animals.
3. The Thirty-Day Rule
| When | What happens | Detail |
|---|---|---|
| Day 0 | IND submitted | 2024-09-06 |
| Days 0–30 | FDA reviews for safety to proceed | Not an assessment of whether the drug works. Whether participants would be at unreasonable risk. |
| Day 30 | The IND becomes effective automatically | 2024-10-06 |
| Any time | Clinical hold may be imposed | Before day 30 or years later. A hold stops dosing until resolved. |
The review in those thirty days asks one question: would participants be exposed to unreasonable and significant risk? Not whether the drug works, not whether the program is sensible, not whether the design is elegant. Safety to proceed.
For a program manager the practical implication is a scheduling one that catches people out. The thirty days are not negotiable, cannot be expedited, and run on calendar days. A program that plans first-in-human dosing for the week after IND submission has planned to break federal law.
Why Gate 2 released no money
The Charter records Gate 2 as a submission gate carrying no tranche, and this is why. The gate authorized filing. What happens next is a regulatory clock the sponsor does not control and cannot influence — so there is nothing to fund, and no decision to take, until the thirty days elapse.
4. Amendments Do Not Restart the Clock
The thirty-day wait applies to the original IND. It does not apply again, and the difference is one people coming to this from outside consistently get wrong.
| Submission | May work begin? | Conditions |
|---|---|---|
| Original IND | After 30 days | Automatic, provided the agency has not acted. |
| New protocol under an existing IND | On submission | Provided the IND is in effect and the protocol has IRB approval. No waiting period. |
| Change to an existing protocol | On submission | Same conditions. Changes that eliminate an immediate hazard may be implemented before submission. |
| New investigator | On submission | Notification, not approval. |
That is why the schedule shows Phase 3 starting the day after Gate 4 rather than a month later, and it is a genuine planning distinction: a program that budgets a thirty-day regulatory wait before each phase has built a delay that does not exist.
The regulation puts participant safety ahead of its own notification requirements. That is the correct ordering and it is rarely used — but a program that does not know the provision exists will delay a protective change while it prepares a submission.
4. Clinical Hold
The agency's power under an IND is not to approve. It is to stop.
| Ground for a clinical hold | Note |
|---|---|
| Unreasonable risk to participants | The core ground. Usually a safety signal. |
| Investigators not qualified | Rare, and remediable. |
| Investigator's Brochure misleading or incomplete | A documentation ground with clinical consequence — investigators cannot consent participants against an inaccurate risk picture. |
| IND does not contain enough information to assess risk | The most common ground on an original IND. |
| Design deficient to meet its stated objectives | Applies to Phase 2 and 3 — an unanswerable study exposes participants for nothing. |
That is why the RAID Log treats regulatory action as a standing constraint rather than a phase-specific risk, and why it sits among the matters outside Development Committee authority. A committee cannot vote to continue dosing under a hold.
The third ground repays attention because it looks administrative and is not. An Investigator's Brochure that is misleading or incomplete is a hold ground on its own — because investigators consent participants against the risk picture it contains. An inaccurate IB means participants agreed to something other than what they were actually accepting.
This program has had no clinical hold. That is the expected outcome and worth stating rather than assuming: the absence of a hold across 8 years and 2,480 randomized participants is part of what the review was assessing when it looked at whether the clinical package could be trusted.
5. The IND Is a Living File
An original IND is a snapshot. What matters over 8 years is everything filed since.
| Submission type | Count | What it covers | Note |
|---|---|---|---|
| Protocol amendments | 31 | New protocols, changes to existing ones, new investigators. | Each new phase, each design change, each of 231 activated sites. |
| Information amendments | 18 | New CMC, nonclinical or clinical information. | Includes the manufacturing site change to Aldergate. |
| IND safety reports | 44 | Expedited 7-day and 15-day reports. | See the Safety Reporting Plan. |
| Annual reports | 2 | Progress, safety summary, and the plan for the coming year. | Due within 60 days of the IND anniversary. |
| Investigator's Brochure updates | 4 | Editions issued as the safety database grows. | Currently v4. Each edition changes what counts as 'unexpected'. |
99 submissions to a single IND across 8 years — and each one is a regulatory act with its own requirements, timelines and consequences.
312.50, and it is the one most easily under-resourced because it looks like
administration.It is not. A protocol amendment that is filed late means a site enrolling under a protocol version the agency has not seen. An annual report that is missed is a compliance failure on a live application. An Investigator's Brochure that is not updated when the safety database moves means the program is assessing expectedness against a stale reference — and therefore reporting the wrong things on the wrong clocks.
Note the Investigator's Brochure line specifically. Four editions in 8 years, each one changing what counts as unexpected. An event that generated a fifteen-day report in 2025 may require no expedited report in 2028 — not because the event changed, but because the reference did.
7. How INDs Actually Get Into Trouble
Not through dramatic failures. Through maintenance.
| Failure | How it happens | Consequence |
|---|---|---|
| Enrolling under an unsubmitted amendment | A protocol change is agreed operationally and reaches sites before it reaches the agency. | Participants enrolled under a protocol version FDA has not seen. A GCP finding and a data-integrity question over every affected participant. |
| A stale Investigator's Brochure | The safety database moves; the IB does not. | Expectedness assessed against the wrong reference — so expedited reports are filed on the wrong clocks, or not at all. |
| A missed annual report | It looks like paperwork and has no internal deadline. | A compliance failure on a live application, and the first thing an inspector checks for pattern. |
| Obligations transferred but not recorded on Form 1571 | A CRO takes on work that the written transfer never described. | Under 312.52 the obligation was never transferred — it is still the sponsor's, and the sponsor was not exercising it. |
| Losing track of which protocol version a site is running | 231 sites, 31 protocol amendments, and no single controlling register. | Discovered at inspection rather than by the sponsor. |
It is also why “maintaining an effective IND” is a named sponsor obligation rather than a task. The IND is the only artifact that is continuously live from first-in-human to post-marketing — and the only one where being six weeks behind is not a delay but a compliance state.
6. From IND to NDA
| IND | NDA | |
|---|---|---|
| What it is | An exemption claimed by the sponsor | An application for approval |
| Who acts | Nobody — effective by operation of regulation | FDA, within a defined review period |
| Default outcome | Proceed, unless the agency objects | Nothing, until the agency acts |
| Agency power | To stop (clinical hold) | To approve, or not |
| CMC required | Safety of clinical supply | Full commercial process, validated and inspected |
| Size | One volume set | ~106,200 pages plus datasets |
| Duration | Open for the life of development | Reviewed once, then a lifecycle |
Everything about how the two are managed follows from that inversion. An IND is maintained; an NDA is prosecuted.
The IND does not close at approval. It remains open to support post-marketing studies — including PMR-1, the deferred pediatric study reporting in 2034, which will be conducted under this same IND four years after the program that opened it has been dissolved.